Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00471536 · OUTCOME

Time to Disease Progression

Pazopanib in Treating Patients With Metastatic Urothelial Cancer · Source last updated 2014-05-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Every 3 months from registration until progressive disease (PD), assessed up to 2 years after registration

What was measured

The distribution of progression-free survival times will be estimated using the Kaplan-Meier method.

Analysis population: All participants were evaluable for this endpoint.

Groups in this outcome

Treatment (Enzyme Inhibitor Therapy)

Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Enzyme Inhibitor Therapy)19

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Enzyme Inhibitor Therapy)1.85Not reported1.773.71Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.77
        upper Limit
        3.71
        value
        1.85
denoms
  1. counts
    1. group Id
      OG000
      value
      19
    units
    Participants
description
The distribution of progression-free survival times will be estimated using the Kaplan-Meier method.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Enzyme Inhibitor Therapy)
param Type
MEDIAN
population Description
All participants were evaluable for this endpoint.
reporting Status
POSTED
time Frame
Every 3 months from registration until progressive disease (PD), assessed up to 2 years after registration
title
Time to Disease Progression
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice